Abstract:Importance Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer, with approximately 60 430 new diagnoses expected in 2021 in the US. The incidence of PDAC is increasing by 0.5% to 1.0% per year, and it is projected to become the second-leading cause of cancer-related mortality by 2030. Observations Effective screening is not available for PDAC, and most patients present with locally advanced (30%-35%) or metastatic (50%-55%) disease at diagnosis. A multidisciplinary management approach is recommended. Localized pancreas cancer includes resectable, borderline resectable (localized and involving major vascular structures), and locally advanced (unresectable) disease based on the degree of arterial and venous involvement by tumor, typically of the superior mesenteric vessels. For patients with resectable disease at presentation (10%-15%), surgery followed by adjuvant chemotherapy with FOLFIRINOX (fluorouracil, irinotecan, leucovorin, oxaliplatin) represents a standard therapeutic approach with an anticipated median overall survival of 54.4 months, compared with 35 months for single-agent gemcitabine (stratified hazard ratio for death, 0.64 [95% CI, 0.48-0.86]; P = .003). Neoadjuvant systemic therapy with or without radiation followed by evaluation for surgery is an accepted treatment approach for resectable and borderline resectable disease. For patients with locally advanced and unresectable disease due to extensive vascular involvement, systemic therapy followed by radiation is an option for definitive locoregional disease control. For patients with advanced (locally advanced and metastatic) PDAC, multiagent chemotherapy regimens, including FOLFIRINOX, gemcitabine/nab-paclitaxel, and nanoliposomal irinotecan/fluorouracil, all have a survival benefit of 2 to 6 months compared with a single-agent gemcitabine. For the 5% to 7% of patients with a BRCA pathogenic germline variant and metastatic PDAC, olaparib, a poly (adenosine diphosphate [ADB]-ribose) polymerase inhibitor, is a maintenance option that improves progression-free survival following initial platinum-based therapy. Conclusions and Relevance Approximately 60 000 new cases of PDAC are diagnosed per year, and approximately 50% of patients have advanced disease at diagnosis. The incidence of PDAC is increasing. Currently available cytotoxic therapies for advanced disease are modestly effective. For all patients, multidisciplinary management, comprehensive germline testing, and integrated supportive care are recommended.

Pancreatic cancer: A review of epidemiology, trend, and risk factors

Rising Trends in Pancreatic Cancer Incidence and Mortality in 2000-2014

Pancreatic Cancer Epidemiology, Detection, and Management

Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment

Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors

Advances In The Epidemiology Of Pancreatic Cancer: Trends, Risk Factors, Screening, And Prognosis

Epidemiology of Pancreatic Cancer: New Version, New Vision

Worldwide Burden Of, Risk Factors For, and Trends in Pancreatic Cancer.

Epidemiological Characteristics of Pancreatic Cancer in China From 1990 to 2019

Pancreatic Cancer: A Review of Risk Factors

An Overview of Pancreatic Cancer Diagnosis and Treatment in China: Current Landscape and Future Prospects

Pancreatic cancer incidence and mortality patterns in 2006-2015 and prediction of the epidemiological trend to 2025 in China

Current status and progress of pancreatic cancer in China

Recent Advances in Basic Research, Clinical Diagnosis and Treatment of Pancreatic Cancer in 2015

Global Patterns and Trends in Pancreatic Cancer Incidence: Age, Period, and Birth Cohort Analysis

Pancreatic Cancer: A Review.

Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection

Pancreatic cancer challenge in 52 Asian countries: age-centric insights and the role of modifiable risk factors (1990-2019)

Advances in basic research,clinical diagnosis and treatment of pancreatic cancer in 2023

Current Status and Future Prospect of Surgical Treatment for Pancreatic Cancer

High Risk Factors of Pancreatic Carcinoma